Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

This study has been terminated.
(Stopped due to futility.)
Sponsor:
Information provided by (Responsible Party):
Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier:
NCT01038739
First received: December 22, 2009
Last updated: May 15, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)